Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Depreciation & Amortization (CF) (2016 - 2025)

Medifast (MED) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 8.79% year-over-year to $3.5 million, compared with a TTM value of $14.2 million through Dec 2025, up 12.08%, and an annual FY2025 reading of $14.2 million, up 12.08% over the prior year.
  • Depreciation & Amortization (CF) was $3.5 million for Q4 2025 at Medifast, roughly flat from $3.5 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $4.0 million in Q2 2025 and bottomed at $1.1 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $2.9 million, with a median of $3.1 million recorded in 2024.
  • Peak annual rise in Depreciation & Amortization (CF) hit 422.91% in 2021, while the deepest fall reached 32.25% in 2021.
  • Year by year, Depreciation & Amortization (CF) stood at $3.0 million in 2021, then fell by 2.99% to $3.0 million in 2022, then rose by 13.51% to $3.4 million in 2023, then dropped by 5.01% to $3.2 million in 2024, then increased by 8.79% to $3.5 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for MED at $3.5 million in Q4 2025, $3.5 million in Q3 2025, and $4.0 million in Q2 2025.